Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...

The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is the ...

Inebilizumab significantly reduced the risk of treated and AC-determined IgG4-RD flare by 87% compared with placebo. The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab ...

Tevimbra is a humanised immunoglobulin G 4 (IgG4 ... The antibody is engineered to decrease the interaction with Fc-gamma ...

Mårtensson, L., Proc. Eleventh Cong. Intern. Soc. Blood Transf., Sydney 1966, Bibl. Haemat., No. 29, Part 2, 510 (Karger, Basel and New York, 1968).